Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., explained in plain language.
Biopharmaceutical company focused on antibody-drug conjugates (ADCs) and oncology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug duo aims to slow advanced lung cancer in first-line trial Results expected Nov 2026 (estimated)
- New hope for advanced breast cancer: A166 takes on T-DM1 in head-to-head trial Results expected Nov 2026 (estimated)
- New hope for lung cancer patients who can't use standard immunotherapy alone Results expected Dec 2026 (estimated)
- New cancer drug SKB571 enters first human tests Results expected Dec 2026 (estimated)
- New drug SKB264 targets Hard-to-Treat cancers in Mid-Stage trial Results expected Dec 2026 (estimated)
-
New drug SKB571 tested against deadly pancreatic cancer
Disease control Not yet recruitingResearchers are testing an investigational drug called SKB571 in adults with advanced or metastatic pancreatic cancer. The trial aims to see how well the drug shrinks tumors and how safe it is. Participants receive SKB571 every three weeks, and doctors track their response using …
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a new infusion drug shrink Hard-to-Treat breast tumors?
Disease control Not yet recruitingThis trial is testing an investigational drug called SKB103 in people with advanced HER2-negative breast cancer that has not responded to standard treatments. The study has two parts: first, to find a safe dose, and second, to see how well that dose shrinks tumors. Participants r…
Phase 1/2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug combo aims to shrink advanced stomach tumors
Disease control Not yet recruitingThis study tests a new drug combination (SKB315 plus an immunotherapy) in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 80 participants in China will receive the treatment to see if it shrinks tumors. The goal is to cont…
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC